Author: Editor

Nancy E. Davidson, MD of Seattle Cancer Care Alliance gives an overview of a joint session between American Association of Cancer Research (AACR) and American Society of Clinical Oncology (ASCO) on two types of liquid biopsies, circulating tumor cells and circulating tumor DNA. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Nancy E. Davidson, MD of Seattle Cancer Care Alliance discusses plans the center has on the future of cost and affordability for cancer care at the 2017 ASCO Annual Meeting in Chicago, IL.

Shinji Atagi, MD of National Hospital Organization Kinki-Chuo Chest Medical Center gives an overview of a randomized trial done by the Japan Clinical Oncology Group on radiotherapy for elderly NSCLC patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8532: Randomized trial of thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer (NSCLC): Long-term follow-up of Japan Clinical Oncology Group (JCOG) Study JCOG0301

Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. discusses what’s next for entrectinib and his hopes to launch the drug globally in the next couple of years. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. gives an overview of his clinical trial, STARTRK-2 and the use of entrectinib, an investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors, at the 2017 ASCO Annual Meeting in Chicago, IL.

Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. explains the impact of Entrectinib and the STARTRK-2 trial on clinical practice and future clinical trials. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. explains genomic testing in finding patients for the clinical trial, STARTRK-2. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. STARTRK-2: A Phase II Study on Use of Entrectinib in NTRK1/2/3, ROS1, or ALK Gene Fusions

David Michael Hyman, MD of Memorial Sloan-Kettering talks of his hopes for LOXO-101 in future clinical practice and clinical trials at the 2017 ASCO Annual Meeting in Chicago, IL. LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers

David Michael Hyman, MD of Memorial Sloan-Kettering gives an overview his presentation, which focuses on the efficacy of larotrectinib (LOXO-101) in adult and pediatric TRK fusion cancers at the 2017 ASCO Annual Meeting in Chicago, IL. LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

David Michael Hyman, MD of Memorial Sloan-Kettering explains common questions physicians ask him concerning his study on the efficacy of larotrectinib (LOXO-101). This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers

William P. Harris, MD of Seattle Cancer Care Alliance gives an overview of some of the promising data coming out of ASCO 2017 in Chicago, IL. He discusses several trials for treatment of advanced intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC)

William P. Harris, MD of Seattle Cancer Care Alliance discusses the treatment trends for upper gastrointestinal cancers, which include targeted therapy and immunotherapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

William P. Harris, MD of Seattle Cancer Care Alliance explains some of the common questions asked regarding the phase II trial on pancreatic cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4008: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).

William P. Harris, MD of Seattle Cancer Care Alliance discusses metastatic pancreatic cancer for the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4008: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).

Julie R. Gralow, MD of Seattle Cancer Care Alliance gives an overview of her presentation, SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 521: SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy

Julie R. Gralow, MD of Seattle Cancer Care Alliance explains the impact of the trial on clinical practice, arguing that the data now shows the important role PARP inhibitors have in metastatic breast cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 521: SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy

Davendra Sohal, MD of Cleveland Clinic discusses the treatment trends for pancreatic cancer, which include understanding the mechanisms of resistance to current therapies. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Davendra Sohal, MD of Cleveland Clinic discusses the impact of perioperative chemotherapy on management of resectable pancreatic cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. TPS4152: Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

Davendra Sohal, MD of Cleveland Clinic gives an overview of his presentation, Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL. TPS4152: Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center discusses the impact of the talimogene laherparepvec and ipilimumab combination in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma

Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center talks of his hopes for the expansion of talimogene laherparepvec across multiple cancer types for future clinical research. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center discusses the most exciting and interesting presentations coming out of ASCO 2017, which include three oral presentations, focusing on the efficacy of FDA-approved combination regiments in melanoma patients who have brain metastases. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center talks of the common questions most physicians ask regarding his study on talimogene laherparepvec and ipilimumab in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma

Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center gives an overview of his presentation which focused on the use of talimogene laherparepvec and ipilimumab versus ipilimumab alone in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma

Bernardo H. Goulart, MD, MS of Seattle Cancer Care Alliance explains the impact of natural language processing (NLP) on future clinical practice and trials. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 6528: Validation of natural language processing (NLP) for automated ascertainment of EGFR and ALK tests in SEER cases of non-small cell lung cancer (NSCLC).

Bernardo H. Goulart, MD, MS of Seattle Cancer Care Alliance discusses the use of natural language processing (NLP) for patients with non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 6528: Validation of natural language processing (NLP) for automated ascertainment of EGFR and ALK tests in SEER cases of non-small cell lung cancer (NSCLC).

Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center gives an overview of his current clinical studies, which focus on the use of mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer patients Abstract 5547: Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts Abstract TPS5607: FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FR?)-positive, platinum-resistant…

Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center discusses a collaborated study with Dr. Dr. Jalid Sehouli of AGO and Charité Campus Virchow-Klinikum, Berlin, Germany, that focuses on the clinical characteristics of long-term ovarian cancer survivors. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract e17063: Clinical characterization of long term survivors (LTS) in ovarian cancer (OC): Results of a propensity score matched (PSM) analysis of the international prospective tumor bank for ovarian cancer (TOC Network)

Michael J. Birrer, MD, PhD discusses his role as newly appointed director for the University of Alabama at Birmingham Comprehensive Cancer Center and his future plans and goals for the hospital. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center gives an overview of presentation that involves the use of avelumab in patients with endometrial cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract TPS5615: Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and POLE-mutated recurrent or persistent endometrial cancer

Manmeet S. Ahluwalia, MD of Cleveland Clinic discusses three abstracts presented at ASCO 2017, highlighting the management of brain metastases in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9506: COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600mutant (mut) melanoma brain metastases (MBM) presented by Dr. Michael A. Davies of MD Anderson Cancer Center Abstract 9507: Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204 presented by…

Manmeet S. Ahluwalia, MD of Cleveland Clinic gives an overview of his presentation, What Drives Patient Outcomes in Brain Metastases: Number, Volume, or Biology, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 2071: What Drives Patient Outcomes in Brain Metastases: Number, Volume, or Biology?

Vivek Subbiah, MD of MD Anderson Cancer Center discusses the impact of his study of vemurafenib in NSCLC patients on clinical practice and future clinical research. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9074: Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600mutation.

Vivek Subbiah, MD of MD Anderson Cancer Center discusses the exciting and new data presented at ASCO, which shows promise for the future of precision oncology and personalized therapy. This was recorded at the 2017 ASCO Annual Meeting.

Vivek Subbiah, MD of MD Anderson Cancer Center gives an overview of his presentation, which focused on the use of vemurafenib in patients with non small-cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9074: Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600mutation.

Alan P. Venook, MD of UCSF Helen Diller Family Comprehensive Cancer Center gives an overview of his presentation, which focused on the difference between left and right sided tumors in patients with colon cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Alan P. Venook, MD of UCSF Helen Diller Family Comprehensive Cancer Center gives an overview of the exciting presentations discussed at ASCO this year. One particular presentation he is most interested in focuses on the treatment of stage III colon cancer with adjuvant therapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute discusses the common questions and concerns regarding her presentation on commercially prescribed PD-1 inhibitors in non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute gives an overview of her presentation, Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9087: Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting.

Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute discusses the treatment trends for lung cancer and oncology overall, which include combination therapy and immune checkpoint inhibitors. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Alok Khorana, MD of Cleveland Clinic gives an overview his presentation, which focuses on time to initiating (TTI) cancer therapy for common solid tumors. Data suggests an increase in TTI is associated with substantial increase in mortality. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 6557: Time To Initiating Cancer Therapy Is Increasing And Associated With Worsened Survival In Curative Settings: A US Analysis of Common Solid Tumors

Alok Khorana, MD of Cleveland Clinic discusses the skepticism surrounding timing to initiating (TTI) cancer therapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Alok Khorana, MD of Cleveland Clinic gives an overview of the treatment trends for gastrointestinal cancers, which includes the use of adjuvant therapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Daniel A. Goldstein, MD of Davidoff Cancer Center gives an overview of the treatment trends for non-small cell lung cancer for 2017, which include new approvals for immunotherapies. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL

Daniel A. Goldstein, MD of Davidoff Cancer Center discusses the impact of weight-based dosing on patients’ affordability of the drug. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL

Daniel A. Goldstein, MD of Davidoff Cancer Center explains the questions regarding the equivalence of dosing in milligrams versus milligrams per kilograms. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9013: A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer.

Daniel A. Goldstein, MD of Davidoff Cancer Center gives an overview of his presentation, involving dosing of pembrolizumab in non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9013: A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the challenges of the AIM2CERV trial at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the take-home message coming out of ASCO 2017, which includes the breakthrough of immunotherapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center explains the importance of targeting HPV-associated cancers. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center explains the goal of the AIM2CERV trial, which is to evaluate whether or not axalimogene filolisbac can prevent or reduce the risk of cervical cancer recurrence after patients received the initial standard of care. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the use of AIM2CERV’s axalimogene filolisbac for the treatment of HPV-associated cancers, including cervical cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center gives an overview of his presentation, AIM2CERV: Global Phase 3 Trial of Advaxis Axalimogene Filolisbac for Cervical Cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the impact of the AIM2CERV study on patients with cervical cancer and on clinical practice. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. discusses the most common questions he has been asked regarding the ENCORE study, which are: what are the characteristics of the patients that went into the study, how long has it been since the patients progressed, and are these patients who initially had a response and then progress? This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. gives an overview of a few presentations that he finds the most promising from the 2017 ASCO Annual Meeting in Chicago, IL.

Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. gives an overview of his presentation, Abstract #9529 ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL.

Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. discusses the treatment trends in 2017 for advanced melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Krishnansu S. Tewari, MD of University of California, Irvine explains what CA4P is. CA4P is a vascular disrupting agent (VDA), which is thought to work by blocking the blood supply inside the tumor, depriving it of oxygen and nutrients, which leads to cell death. CA4P is being developed by Mateon Therapeutics in South San Francisco, CA. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Krishnansu S. Tewari, MD of University of California, Irvine discusses the most recent results from the FOCUS trial, including the first interim analysis which evaluated the safety of the drug as well as early signs of efficacy. The trial is sponsored by Mateon Therapeutics in South San Francisco, CA This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Krishnansu S. Tewari, MD of University of California, Irvine gives an overview of the FOCUS trial, which is sponsored by Mateon Therapeutics in South San Francisco, CA. The FOCUS trial is a double-blind, randomized, phase 2/3 clinical study evaluating the efficacy and safety of physicians choice chemotherapy plus bevacizumab and CA4P versus physicians choice chemotherapy plus bevacizumab and placebo in patients with platinum-resistant ovarian cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL

Krishnansu S. Tewari, MD of University of California, Irvine discusses the impact of the FOCUS trial on clinical practice, explaining how the trial gives ovarian cancer patients another option for treatment.

Mark Rutstein, Vice President of Oncology Development of Bayer discusses the xofigo injection, a treatment method for patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of three abstracts that discussed the use of regorafenib (stivarga) in advanced colorectal cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract #3567: Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study Abstract #3551: Handfoot skin reaction (HFSR) and outcomes in the phase 3 CORRECT trial of regorafenib for metastatic colorectal cancer (mCRC) Abstract #4078: Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in…

Mark Rutstein, Vice President of Oncology Development of Bayer discusses his take on the treatment trends for 2017 and 2018, which include the growth of immunotherapy and therapy tailored to individual patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Mark Rutstein, Vice President of Oncology Development of Bayer discusses the RIFTOS trial, which focused on the use of sorafenib for thyroid cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract #6084: Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)

Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of two poster presentations that focus on the use of Copanlisib for relapsed or refractory follicular lymphoma and relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Poster #7535: Copanlisib in patients with relapsed or refractory follicular lymphoma Poster #7536: Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Mark Rutstein, Vice President of Oncology Development of Bayer discusses Bayers current and approved products and new and diverse advances for its robust oncology pipeline. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of the ARASENS study, which is a phase 3 trial on the use of darolutamide for men with metastatic hormone-sensitive prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract #TPS5092: ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Howard S. Hochster, MD of Yale School of Medicine gives an overview of his presentation, The Impact of Molecular Subsets on Adjuvant and Advanced Disease Treatment, which was discussed at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Howard S. Hochster, MD of Yale School of Medicine discusses the importance of recommending molecular testing early on to patients with colon cancer. He further explains the significance of HER2 testing in colon cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Howard S. Hochster, MD of Yale School of Medicine discusses the impact of molecular testing and screening on potential clinical trials at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Christopher Crane, MD of Memorial Sloan-Kettering gives an overview of his presentation, What is the Optimal Neoadjuvant Strategy in Pancreatic Cancer, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Christopher Crane, MD of Memorial Sloan-Kettering gives an overview of his presentation, Does Radiation Therapy Play a Role in Gastric Cancer Adjuvant Therapy, which was debated with Dr. David Ilson, MD, PhD of Memorial Sloan-Kettering. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Mark A. Schattner, MD of Memorial Sloan-Kettering gives an overview of his presentation, Novel Endoscopic Management of Pancreaticobiliary Cancers, which was presented at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Mark A. Schattner, MD of Memorial Sloan-Kettering explains whether or not there is screen for pancreatic cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

David Ilson, MD, PhD of Memorial Sloan-Kettering discusses questions from the audience that focused on the appropriate chemotherapy for gastric cancer treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

David Ilson, MD, PhD of Memorial Sloan-Kettering explains the impact of radiation therapy on clinical practice. He argues that adding radiation therapy as an obligatory part of adjuvant therapy does not improve overall survival. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

David Ilson, MD, PhD of Memorial Sloan-Kettering gives an overview of his presentation, Debate: Does Radiation Therapy Play a Role in Gastric Cancer Adjuvant Therapy, which was debated with Dr. Christopher Crane, MD of Memorial Sloan-Kettering. He argues that adjuvant radiation therapy adds no benefit to treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Ghassan Abou-Alfa, MD of Memorial Sloan-Kettering discusses his presentation, Overview of Novel Treatments for HCC in the Era of Hep C Therapies, which was discussed at the 2016 Great Debates and Updates in GI Malignancies in New York, NY

Ghassan Abou-Alfa, MD of Memorial Sloan-Kettering discusses the impact of regorafenib for hepatocellular carcinoma (HCC) treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Jonathan R. Strosberg, MD of Moffitt Cancer Center gives an overview of his presentation, Management of Neuroendocrine Tumors, which was discusses at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Jonathan R. Strosberg, MD of Moffitt Cancer Center discusses the impact of circulating tumor DNA on oncology treatment and management. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Jonathan R. Strosberg, MD of Moffitt Cancer Center gives an overview of his presentation, Is There a Role for Surgical Management of Metastatic Neuroendocrine Cancer, which was debated with Dr. Michael Choti, MD, MBA of UT Southwestern Medical Center. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Yelena Yuriy Janjigian, MD, Memorial Sloan-Kettering gives an overview of her presentation, Molecular Subtyping/Profiling and Update in HER2 Targeted Therapy, which was discussed at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Yelena Yuriy Janjigian, MD of Memorial Sloan-Kettering explains whether or not PDL-1 is a sufficient biomarker in gastric disease. She argues that clinicians should consider a one-stop next generation sequencing. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, New York.

Yelena Yuriy Janjigian, MD of Memorial Sloan-Kettering discusses her presentation, Is Surgery Required After Chemoradiotherapy for Squamous Cancer of the Esophagus, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY. She argues that surgery is a must after chemo-radiation.

http://cancertherapeutics.alliedacademies.com/

Cathy Eng, MD, FACP of MD Anderson Cancer Center discusses her second presentation, which focused on management of anal carcinoma. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Cathy Eng, MD, FACP of MD Anderson Cancer Center gives an overview of her first presentation, Is Circulating Tumor DNA Ready to Guide Adjuvant Therapy in Colon Cancer, which was debated with Dr. Axel Grothey of Mayo Clinic, at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Michael Choti, MD, MBA of UT Southwestern Medical Center gives an overview of his presentation, Is There a Role for Surgical Management of Metastatic Neuroendocrine Cancer, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Michael Choti, MD, MBA of UT Southwestern Medical Center discusses questions from the audience on how to manage early stage neuroendocrine tumors or tumors that are incidentally found. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Zsofia K. Stadler, MD of Memorial Sloan-Kettering explains the role of aspirin therapy in patients with colon cancer and other GI malignancies. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Zsofia K. Stadler, MD of Memorial Sloan-Kettering gives an overview of her second presentation, which focused on the role of genetics in gastrointestinal cancers. She further discusses who should be tested for hereditary syndromes and why. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic gives an overview of his second presentation, which focused on optimal adjuvant chemotherapy for resected pancreatic cancer. He further explains the use of gemcitabine and capecitabine for treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic explains whether or not there is a standard second line treatment for patients with hepatocellular carcinoma (HCC) and who failed first line therapy. He argues that Regorafenib should be used for second line therapy. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic gives an overview of his first presentation, which focused on the availability of new novel agents and therapies for managing patients with metastatic colorectal cancer. He discusses the uses of HER2, BRAF, and Immunotherapy. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic explains how to integrate HER2, BRAF, and immunotherapy into clinical practice. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Eric Van Cutsem, MD, PhD of University of Leuven gives an overview of his presentation which focused on how to treat left-sided tumors versus right-sided tumors in colorectal cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Eric Van Cutsem, MD, PhD of University of Leuven gives an overview of his second presentation, which focused on the role of novel agents in colorectal cancer patients. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Eric Van Cutsem, MD, PhD of University of Leuven discusses the impact of left-sided tumors versus right-sided tumors on research in colorectal cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Scott Kopetz, MD, PhD, FACP of MD Anderson Cancer Center discusses the use of technology and its potential breakthroughs for managing patients with colon cancers at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Scott Kopetz, MD, PhD, FACP of MD Anderson Cancer Center gives an overview of his presentation, which focused on treatment of left versus right sided colon cancers. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Scott Kopetz, MD, PhD, FACP of MD Anderson Cancer Center gives an overview of the novel therapies that are being used for colon cancer treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Christopher Leigh Hallemeier, MD of Mayo Clinic gives an overview of Dr. Julio Garcia-Aguilar’s latest research trial, A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management, at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Christopher Leigh Hallemeier, MD of Mayo Clinic gives an overview of his presentation, Is Observation Without Surgery Reasonable for Rectal Cancers Achieving a Clinical CR, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Christopher Leigh Hallemeier, MD of Mayo Clinic explains whether or not clinicians can use non-operative management for patients with stage I rectal cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Julio Garcia-Aguilar, MD, PhD of Memorial Sloan-Kettering gives an overview of new data regarding watch-and-wait approaches in patients with rectal cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Julio Garcia-Aguilar, MD, PhD of Memorial Sloan-Kettering gives an overview of his presentation, Is Observation Without Surgery Reasonable for Rectal Cancers Achieving a Clinical CR, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Julio Garcia-Aguilar, MD, PhD of Memorial Sloan-Kettering discusses patient concerns of risks with delaying surgery months or years after receiving neoadjuvant therapy. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

http://cancertherapeutics.alliedacademies.com/ Cancer Therapeutics 2017 will be a great platform for research scientists and young researchers to share their current findings in the field of applied sciences.

Crystal S. Denlinger, MD, FACP of Fox Chase Cancer Center gives an overview of her presentation, which discusses the survivorship care basics for survivors of colorectal cancer. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Crystal S. Denlinger, MD, FACP of Fox Chase Cancer Center gives an overview of her poster presentation, which was a 12-week home-based walking intervention for patients with advanced pancreatic cancer. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Crystal S. Denlinger, MD, FACP of Fox Chase Cancer Center explains the importance of clinicians speaking about diet, exercise, and healthy living with colorectal cancer survivors. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Becky Lowry, MD of University of Kansas Medical Center gives an overview of her presentation, Survivorship Transitions to Adulthood and Using Telemedicine in Rural Areas, which was presented at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Becky Lowry, MD of University of Kansas Medical Center discusses the importance of communication between clinicians and survivors during survivorship care. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Junne Kamihara, MD, PhD of Dana-Farber Cancer Institute gives an overview of her presentation, TP53 Mutation Carriers: Cancer Genetics in Survivorship Care, which was presented at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Junne Kamihara, MD, PhD of Dana-Farber Cancer Institute explains the significance of the shift from single gene testing to multiplex testing.This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Angela R. Bradbury, MD of Perelman School of Medicine at the University of Pennsylvania discusses the integration of information on genetic testing into clinical care. She states that with more discussion on genetic testing, more patients will be encouraged to receive testing. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Angela R. Bradbury, MD of Perelman School of Medicine at the University of Pennsylvania discusses the challenges that came with incorporating genetic testing into survivorship care. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Angela R. Bradbury, MD of Perelman School of Medicine at the University of Pennsylvania gives an overview of the key points clinicians should know when speaking with patients about genetic testing. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Grant Stewart, MBChB, FRCSEd (Urol), PhD, from the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses novel treatments for renal cell carcinoma (RCC) at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the efficacy of combination therapies which can enhance the efficacy of known drugs. Dr Stewart also describes challenges associated with having multiple combination approaches available, and speaks about new approaches to identify good drug combinations.

Gerald Mickisch, MD, from the Bremen Center of Operative Urology, Bremen, Germany, discusses how sequential therapy can be used in the treatment of castration-resistant prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Mickisch explains the efficacy of sequential therapy, and speaks about the order in which treatments are typically given to improve overall survival (OS).

Bertrand Tombal, MD, PhD, Catholic University of Leuven, Leuven, Belgium, discusses the ARASENS trial for prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the three pillars of prostate cancer treatment: androgen deprivation therapy, androgen receptor suppression, and chemotherapy. Prof. Tombal introduces the hypothesis that combining these treatments will improve overall survival (OS), on which the Phase III ARASENS trial (NCT02799602) is based, and outlines the design of this study.

Anne Kiltie, MD, MRCP(UK), FRCR, from the University of Oxford, Oxford, UK, discusses bladder preservation in muscle invasive bladder cancer at the European Association of Urology (EAU) conference 2017 in London, UK. She describes bladder sparing approaches using a combination of chemotherapy and radiotherapy before carrying out surgery to remove the bladder, and how these vary between different countries. Prof. Kiltie highlights her interest in the treatment of elderly patients, for whom not all therapy options may be available.

Morgan Roupret, MD, PhD, from the Pitié-Salpétrière Hospital, Paris, France, discusses what uro-oncologists should know about new drugs in 2017 at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Roupret highlights the importance of clinical implications, and explains why clinicians should be informed about what is most important in the management of the disease and treatment side effects.

Morgan Roupret, MD, PhD, from the Pitié-Salpétrière Hospital, Paris, France, discusses optimization of contemporary bladder cancer care at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights that bladder cancer has been treated with the same tools for over 30 years, and speaks about new therapies which are now available. Prof. Roupret also points out why a multidisciplinary team approach is needed for bladder cancer management.

Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK, discusses the potential of intraprostatic PRX302 injection for prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the advantages of imaging technologies to visualize the tumor, and speaks about how this allows localized treatment to be carried out and what this means for the patient. Prof. Emberton describes different approaches for targeting the tumor, including energy sources and pharmaceutical approaches, and outlines how the effects of the bacterial toxin PRX302 can be limited to the prostate. He speaks…

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Philip D. Bonomi discusses new approaches to the treatment of cachexia. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Nurse Beth Eaby-Sandy discusses how to communicate with families regarding expectations for treatment outcomes. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vera Hirsh discusses the role of zoledronic acid, denosumab, and other strategies in the treatment of bone metastases. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Corey J. Langer discusses the targeting of angiogenesis in non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Ranee Mehra discusses the management of T790-negative EGFR-mutated non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Tracey L. Evans discusses the management of T790-positive EGFR-mutated non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vera Hirsh discusses how, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR-positive non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Barbara A. Burtness discusses current and future strategies for esophageal cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vassiliki Papadimitrakopoulou discusses the changing face of first- and second-line therapy for squamous cell carcinoma. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this discussion, the co-chairs of the European Focus on Myeloproliferative Neoplasms & Myelodysplastic Syndromes 2017 highlight the key points presented during the meeting, with the aim of sharing updates that will help you enhance your clinical practice. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=EMDS © 2017 Imedex, LLC.

Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics describes the effect and consequences of when ER-p53 tumors attach to mutant p53. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics describes his other study that focuses on the use of tamoxifen therapy for triple negative breast cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics discusses how to customize therapy based on the stratification of p53. He further explains with the stratification of p53 status, clinicians can now come up with new strategies for treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics gives an overview of his abstract, Novel effect of tamoxifen therapy: disruption of ER-p53 interaction leading to altered gene expression profile in human breast tumors, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center gives an overview of one of her presentations, The Effects of Tumor Microenvironment on Metastasis and Therapy Resistance , which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center discusses the treatment trends for 2017 in oncology at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center gives an overview of one of her presentations, Taming the Tumor Microenvironment in Pancreatic Cancer, which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center explains the importance in understanding the language of tumors for cancer research and treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center discusses the research on tumor microenvironment and its impact on cancer research and overall standard of care. She argues the research data helps predict potential tumors and can potentially develop novel pathways and novel treatments to help lower risk in patients. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center explains how the genotype of a tumor affects overall tumor behavior and its response to therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Solange Peters, MD, PhD of Lausanne University Hospital discusses the treatment trends for 2017 which include combination therapy and immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Solange Peters, MD, PhD of Lausanne University Hospital discusses whether or not there is a correlation between biomarkers, specifically PD-L1 and tumor mutation burden, and immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Solange Peters, MD, PhD of Lausanne University Hospital discusses the impact of Checkmate-026 on current cancer research, stating the data encourages clinicians to move and assess the biomarkers in all ongoing trials. She also argues that the biomarker can help predict which patients will benefit from early therapeutic treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Solange Peters, MD, PhD of Lausanne University Hospital gives an overview of her presentation, Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage IV or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate -026, which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University discusses the treatment trends for 2017 include immunotherapy and checkpoint inhibitors, but according to him, treatment should focus more on early detection and prevention of cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Athena Matakidou of the Cambridge Cancer Centre discusses Preclinical models of renal cancer at the 12th European International Kidney Cancer Symposium 2017.

Henry Withers of Roswell Park Cancer Institute, Department of Genetics gives an overview of his presentation, Characterization of an off-target RNAi genomic screen hit identifies GPRC6A as a novel suppressor of metastatic chemotaxis and invasiveness, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Henry Withers of Roswell Park Cancer Institute, Department of Genetics discusses how the data can predict which patients are at risk for metastatic disease and his hopes for a potential biomarker that can be used to identify patients with aggressive prostate cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains where to place immunotherapy in overall treatment plans for cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of presentations that were discussed at the AACR 2017 annual meeting. She describes the use of immune checkpoint blocking drugs in four different types of cancers: breast cancer, melanoma, merkel cell carcinoma, and lung cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains the use of ipilimumab and nivolumab in advanced melanoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains the importance of checkpoint inhibitors, specifically avelumab, in merkel cell cancers. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of presentations at the AACR 2017 annual meeting, specifically data results from a clinical trial on triple negative breast cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of the AACR presentations, which focused greatly on immunotherapy, biomarkers, and combinations. She further explains the impact of immunotherapy on all types of cancer treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kazuaki Takabe, MD, PhD of Roswell Park Cancer Institute discusses the use of liquid biopsies of microRNAs as a follow-up method for patients with breast cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kazuaki Takabe, MD, PhD of Roswell Park Cancer Institute describes the lack of immunotherapy in treatment for breast cancer, stating the biggest challenge in breast cancer research is figuring out a way to utilize immunotherapy in treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kazuaki Takabe, MD, PhD of Roswell Park Cancer Institute gives an overview of his abstract, Novel microRNA signature score to predict bone metastasis and prognosis of breast cancer, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kazuaki Takabe, MD, PhD of Roswell Park Cancer Institute discusses whether or not early detection of metastasis can help overall survival in patients with breast cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Brian Rini, MD, Bernard Escudier, MD, James Larkin, MD and Cora N Sternberg, MD outline the challenges and Navigating the RCC Treatment Landscape: Learning from Experience at the 12th European International Kidney Cancer Symposium 2017

Jonathan D. Powell, MD, PhD of Johns Hopkins University, School of Medicine explains what types of tumors would the new drug be useful for? He argues that the new agent would be useful for all tumors since all tumors rely on a specialized metabolism in order to grow. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jonathan D. Powell, MD, PhD of Johns Hopkins University, School of Medicine discusses the treatment trends for 2017 which include combining therapy with targeting metabolism. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jonathan D. Powell, MD, PhD of Johns Hopkins University, School of Medicine explains the importance of targeting metabolism for cancer research. He argues by targeting metabolic pathways, selective tumor cells will be killed, which will enhance not only cancer treatments but immunotherapy as well. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jonathan D. Powell, MD, PhD of Johns Hopkins University, School of Medicine discusses his presentation topic, Immunometabolism in Immunotherapy, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute discusses the treatment trends for 2017 in cancer, which includes immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute explains whether or not AURKA will play a role in melanoma treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute discusses how the data from the AURKA study shows a possibility in combination therapy between MAPK pathway and other inhibitors. He states the future of clinical trials will revolve around this type of combination study. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute gives an overview of his abstract, Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute explains the treatment trends for 2017, which include immunotherapy, t-cell therapy, and combination therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute explains the significance of how tumors evolve from one type of mutation to another. He states that if there is a better understanding of tumor evolution and mutation, clinicians can gain an idea of what needs to be targeted in the future. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute discusses the process of manufacturing products for research at Roswell Park. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute discusses how the persistency of t-cell receptors against cancer can be achieved. He argues with this data, there will be more effective treatments for cancer and lower chances of relapse. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute gives an overview of his presentation, Sustained efficacy of immunotherapy for solid tumors with novel dual CD4/CD8 T cell receptor engineered synergistic combination of hematopoietic stem cells and T cells, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute explains how the new data on T-Cell receptors impacts next generation for immunotherapies. He argues how the harnessing of t-cell receptors to recognize cancer cells will benefit future clinical trials. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Evan W. Alley discusses the role of angioinhibition and immunotherapy in the treatment of mesothelioma. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Charles B. Simone, II elucidates use of IMRT, proton beam, or SBRT in LA-NSC radiation therapy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Charu Aggarwal discusses attempts to integrate novel targeted agents and immunotherapy into the combined modality paradigm. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Tracey L. Evans discusses whether there are any options beyond chemoteray for non-small cell lung cancer (NSCLC) in the adjuvant setting. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Charles B. Simone, II argues in favor of stereotactic body radiation therapy for early stage non-small cell lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Harvey I. Pass argues in favor of surgery for early stage non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Anil Vachani discusses when and how to intervene on a growing pulmonary module. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Anil Vachani discusses the impact of the National Lung Screen Trial. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Shakun M. Malik discusses novel protocol designs in the era of personalized lung cancer therapy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

Jürgen Gschwend, MD, PhD of the Technical University of Munich School of Medicine and Viktor Grünwald MD, PhD of the Hannover Medical School discuss Treating aRCC in Practice: Current and Future Perspectives at the Kidney Cancer European Symposium 2017.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey discusses the treatment trends for 2017. He explains the significance of immunotherapy, but also the potential for intratumoral therapy with combination therapy in future treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey gives an overview of presentations at AACR 2017 and explains the impact of these clinical presentations on future cancer research. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey gives an overview of his current research, a phase II study which involved a newly FDA-approved drug, avelumab, in patients with merkel cell carcinoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey explains whether or not there is a biomarker to better predict which patients respond to treatment. He states there have been studies for potential biomarkers, but none of the data showed significant responses. He advises all patients should undergo this treatment until clinicians find a biomarker. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey explains the impact of data on future research, stating that avelumab is the only FDA approved drug for Merkel Cell Carcinoma, and with moving forward, future research will involve immunotherapy and combination therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey discusses the use of avelumab, a new agent that became available for patients with merkel cell carcinoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University discusses the treatment trends in 2017 for patients with MDS and AML, which include introduction of new agents, combination therapy, and immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University explains how the impact of epigenetic therapy could lead to more randomized studies and new standard of care for patients with MDS and AML. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University gives an overview of presentations at AACR 2017, specifically on immunotherapy. He states that in order to make immunotherapy work better for patients, the idea of combining immunotherapy with epigenetic therapy is a possibility moving forward. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University gives an overview of his presentation, Epigenetic Therapy: What Is It, Where Are We, and What Does the Future Hold?, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University discusses questions of concern on the the toxicity of the new epigenetic drugs and speculation on what happens after treatment with these drugs. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University discusses the importance of discovering and evaluating new epigenetic drugs for cancer research. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University gives an overview of his presentation, Mutational Landscapes of African American Colon Cancers. His presentation was a part of the ‘Minorities in Cancer Research Scientific Symposium: The Role of Diverse Populations in Precision Medicine’ session at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University explains how mutations in genes could potentially be used as biomarkers. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University stresses the importance of finding data from diverse ethnic populations. He argues data from one population might not work or be affective for another. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University discusses the existing social stigmas for ethnic populations in cancer research. He hopes to educate healthcare professionals by removing these misconceptions which will ultimately benefit all diverse groups. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains the use of combination therapy to extend duration of anti-androgen therapy response. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses his hopes for new clinical trials that can better assess patient response for treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses his hopes for new targets to treat Androgen Deprivation Therapy (ADT) Resistant Disease. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains whether or not variant cells pre-exist in tumors or if therapy causes these cells to transform. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains the transformation of cancers into stem-cell phenotypes, which allows them to adapt to different therapies. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics gives an overview of his abstract, Rb1 suppresses prostate cancer metastasis and lineage plasticity underlying castration resistance, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses the treatment trends for prostate cancer in 2017 and gives an overview of an AACR session, which focused on the “Hallmarks of Cancer” and the epigenetic phenomenon that is occurring in cancer research. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Toni Choueiri, MD and David McDermott, MD discusses the Immuno-Oncology: Changing the Treatment Landscape in RCC at the 12th European International Kidney Cancer Symposium 2017

Börje Ljungberg from Umeå University Sweden discusses the Development of Guidelines in a Rapidly Changing Treatment Landscape for the John Fitzpatrick Memorial Lecture at the 12th European International Kidney Cancer Symposium 2017.

Bernard Escudier of the Gustave Roussy discusses Brain mets under I.O. at the 12th European International Kidney Cancer Symposium 2017

Guillermo de Velasco MD, PhD University Hospital 12 de Octubre discusses SBRT for lung metastases: Case report at the 12th European International Kidney Cancer Symposium 2017

Manuela Schmidinger of the Medical University of Vienna discusses the Solitary Bone Mets Spinal at the 12th European International Kidney Cancer Symposium 2017

Camillo Porta, MD of the I.R.C.C.S. San Matteo University Hospital Foundation answers the question How should the next generation of trials address the question of the sequence? at the 12th European International Kidney Cancer Symposium 2017

Gabriel Malouf, MD, PhD of Pitié-Salpêtrière Hospital Defines Optimal 2nd Line Treatment and Sequence: Biomarker at the 12th European International Kidney Cancer Symposium 2017

In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Eric P. Winer looks back at the advances made in the treatment of breast cancer in the last few decades in an effort to elucidate how to best move forward in 2017. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.

In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Dawn L. Hershman discusses the latest insights in breast cancer prevention, survivorship, and health care delivery. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.

In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Constantine Godellas discusses the latest advances in local-regional approaches for the treatment of breast cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.

David McDermott, MD of the Dana-Farber/Harvard Cancer Center outlines and Defines Optimal 2nd Line Treatment and Sequence: Subgroup Analysis from Pivotal Studies and Real World Data at the  12th European International Kidney Cancer Symposium 2017

John B.A.G. Haanen MD PhD of the The Netherlands Cancer Institute discusses Anti-PD1 PDL1 + anti-VEGFR in Kidney Cancer at the  12th European International Kidney Cancer Symposium 2017

Toni K. Choueiri, MD of the Dana-Farber Cancer Institute discusses the changes in first line kidney cancer treatment for 2018 at the  12th European International Kidney Cancer Symposium 2017

Thomas Powles MD of Barts Cancer Institute discusses the Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients at the  12th European International Kidney Cancer Symposium 2017

Hans Hammers, MD, PhD, UT Southwestern discusses the Dual Immune Checkpoint Blockade at the  12th European International Kidney Cancer Symposium 2017

Alain Ravaud, MD.PhD takes the pro side of the debate entitled Adjuvant Therapy Ready For Prime Time In Kidney Cancer at the  12th European International Kidney Cancer Symposium

Tanja de Gruijl, VU University Medical Center discusses Harnessing the sentinel lymph node Translational perspective: LN as the first priming site of the immune system at the  12th European International Kidney Cancer Symposium 2017

Prof. Dr. med. Viktor Grünwald of the Medical School Hannover outlines the Oncologists perspective LN as metastatic spread at the  12th European International Kidney Cancer Symposium 2017

Jose A. Karam, MD, FACS, Associate Professor Department of Urology MD Anderson Cancer Center discusses Surgeons Perspective: LN as a Draining Pattern from the 12th European International Kidney Cancer Symposium 2017

Aung Naing of MD Anderson Cancer Center discusses PEGylated Human IL-10 AM0010 in Combination with Nivolumab in Renal Cell Cancer at the  12th European International Kidney Cancer Symposium 2017

Cynthia Macahilig of the University of Manchester discusses Health-Related Quality of Life, Treatment Satisfaction, and Work Productivity for Patients With Advanced Renal Cell Carcinoma in a Chart Review Across Six Countries  12th European International Kidney Cancer Symposium 2017

Hans J. Hammers, MD of the University of Texas Southwestern Medical Center discusses Updated Results From a Phase I Study of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study from the  12th European International Kidney Cancer Symposium 2017

Krzysztof Krawczyk of the Department of Translational Medicine, Center for Molecular Pathology Lund University, Malmö, Sweden discusses the papillary renal cell carcinoma-derived chemerin, IL-8 and CXCL16 attract and differentiate monocytes at the  12th European International Kidney Cancer Symposium 2017

Saeed Dabestani MD PhD student Lund University, Sweden discusses the Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes a RECUR database analysis at the  12th European International Kidney Cancer Symposium 2017

Axel Bex, MD, PhD, of The Netherlands Cancer Institute in Amsterdam discusses the Challenges in Surgical Trials for Kidney Cancer at the  12th European International Kidney Cancer Symposium

In this activity, meeting co-chair Dr. John P. Leonard provides the key take-home messages from the leukemia, myeloid disorders, and benign hematology sessions at the 2017 Great Debates & Updates in Hematologic Malignancies, held April 7-8, 2017. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7254 © 2017 Imedex, LLC.

In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Kathy S. Albain discusses updates in adjuvant and neoadjuvant therapy for the treatment of breast cancer, and elaborates on the latest data on predictors of benefit. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.

In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Debu Tripathy discusses novel therapeutics for the treatment of breast cancer, with a focus on HER2+ and triple negative disease. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.

In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Hope S. Rugo discusses novel therapeutics for the treatment of breast cancer, with a focus on CDK inhibitors, immunotherapy, and the role of tumor infiltrating lymphocytes. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.

In this activity, meeting co-chair Dr. David P. Steensma provides the key take-home messages from the leukemia, myeloid disorders, and benign hematology sessions at the 2017 Great Debates & Updates in Hematologic Malignancies, held April 7-8, 2017. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7253 © 2017 Imedex, LLC.

In this activity, meeting co-chair Dr. Robert Z. Orlowski provides the key take-home messages from the plasma cell disorder session at the 2017 Great Debates & Updates in Hematologic Malignancies, held April 7-8, 2017. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7252 © 2017 Imedex, LLC.

Dr. Arnaud Mejean, MD presents the challenges in CARMENA from the 2017 12th Annual European Kidney Cancer Symposium, Munich Germany

Dr. Thomas Powles, MD presents the Challenges in Neoadjuvant Biomarker Trials at the 2017 12th Annual European Kidney Cancer Symposium, Munich Germany.

Axel Bex, MD presents Challenges In Surtime at the 2017 12th Annual European Kidney Cancer Symposium, Munich Germany       kidney cancer, challenges in surtime  

Dr. Cora Sternberg, MD presents the P.H.M. deMulder Lecture entitled From cytokines to targeted therapies to immunotherapy30 years of progress in advanced RCC at the 12th Annual 2017 Kidney Cancer European Meeting in Munich, Germany.